Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Coya Therapeutics, Inc.NASDAQ: COYA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $7.21M (cash outflow) fell 1.4% year over year, behind the +23.3% change in trailing-twelve-month net income. Sequentially, it rose 26.2% from the prior quarter. Over 3 fiscal years it compounded at +20.1% a year.
Context
- Net income amounted to 267.1% of revenue in FY2025, down 151.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$25.16M (+18.5%) for the fiscal year ending Dec 2026, a slowdown from the +42.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.21M+26.2% QoQ
- Last fiscal yearDec 2025
- -$21.23M+42.6% YoY
- LTMMar 2026
- -$21.13M+23.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.4% | +33.1% | +34.4 pp |
| 1 year | +42.6% | +18.5% | -24.1 pp |
| 3-year CAGR | +20.1% | -3.4% | -23.6 pp |
| 5-year CAGR | +14.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (21.23M) USD
- Year-over-year change
- -42.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.23M) | -42.6% |
| FY2024 | 2024-12-31 | (14.88M) | -86.3% |
| FY2023 | 2023-12-31 | (7.99M) | +34.8% |
| FY2022 | 2022-12-31 | (12.24M) | -150.3% |
| FY2021 | 2021-12-31 | (4.89M) | — |
Net Income vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 net income of $21.13M is the 10th largest of the 11 companies compared; the peer median is $37.6M.
- Its year-over-year change of +23.3% is the 5th highest of 11, against a peer median of +6.0%.
- Net income amounts to 266.1% of revenue for COYA, versus a peer median of 339.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.13M | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $110M | +489.6% | — | — | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $49.87M | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | $40.23M | +45.6% | +34.5% | — | |
| LTM Mar 2026 | $34.98M | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $33.51M | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $24.17M | -3.2% | -31.5% | 339.3% | |
| LTM Mar 2026 | $21.13M | +23.3% | +20.1% | 266.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M | -67.7% | -30.2% | 288.3% |
| Peer median (excluding COYA) | $37.6M | +6.0% | -14.6% | 339.3% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.